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Abstract Su Jin Kim and coworkers from Korea published
an important study on the relationship of residual renal
function (RRF) and cystatin in pediatric peritoneal dialysis
(PD) patients in this issue of Pediatric Nephrology, both in
anuric patients and patients with RRF. Based on a lack of
correlation between cystatin C and standard small solutebased dialysis adequacy parameters such as Kt/Vurea but a
significant correlation with RRF, the authors concluded that
cystatin C may be a good tool to monitor RRF. The editorial
reviews the available literature in adults, the different
handing between urea and cystatin C, and the determinants
of cystatin C clearance in dialysis patients. In adults, cystatin
C levels are determined predominantly by RRF, but not
exclusively. In anephric hemodialysis and PD patients, there
is a correlation with standard weekly Kt/Vurea. Cystatin C
levels will also depend on ultrafiltration. Despite these
factors that affect cystatin C levels beyond RRF, cystatin C
is a useful parameter for monitoring PD patients that may be
more closely related to long-term outcomes than small solute
adequacy parameters.
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Introduction
Practicing pediatric nephrologists have felt for some time
that prescribing more dialysis should improve outcomes. In
adults, the result of the National Cooperative Dialysis Study
showed a survival benefit with increased dialysis prescription [1]. Disappointingly, no survival benefits with further
increase in small solutes clearances once a certain threshold
level was reached, which were demonstrated in two major
adult trials: the Effects of Increased Peritoneal Clearances
on Mortality Rates in Peritoneal Dialysis: ADEMEX, a
Prospective, Randomized, Controlled Trial (ADEMEX) and
the Effect of Dialysis Dose and Membrane Flux in
Maintenance Hemodialysis (HEMO) studies [2, 3].
However, residual renal clearance as the major predictor
of survival in dialysis patients (both hemodialysis and
peritoneal dialysis) was demonstrated in carefully conducted re-analyses of both studies [4, 5]. As a result, it is
important to monitor and to preserve residual renal
function (RRF) in dialysis patients, as it is a strong
predictor for patient survival in this adult population and
presumably also in children. The Kidney Disease Outcomes
Quality Improvement (KDOQI) clinical practice guideline
recommends monitoring of RRF periodically in patients with
end-stage renal disease [6].
As pointed out in the study from Su Jin Kim and coworkers
from Korea [7] in this issue of Pediatric Nephrology, goldstandard measurements of RRF using inulin clearance or
nuclear medicine techniques such as 99Tc DTPA or 51Cr
EDTA clearance studies are cumbersome and invasive. In
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clinical practice, renal Kt/Vurea are utilized in pediatric
dialysis patients, but unreliable collection of urine and
peritoneal dialysis fluid frequently skew results and provide
inadequate estimates of RRF.
Recent adult studies in adult dialysis patients suggest
that cystatin C levels reflect predominantly (but not
exclusively) renal clearance independent of urine collection, making this an attractive marker for assessment of
RRF [8, 9]. Cystatin C values also correlated inversely to
weekly creatinine clearance and to total [peritoneal dialysis
(PD) + residual renal function] Kt/Vurea. Multiple regression models showed that only the renal components of Kt/
Vurea and weekly creatinine clearance contributed to the
serum cystatin C concentrations. A further study by Hoek
and colleagues [10] also showed that a modeled formula
from plasma cystatin C levels showed better accuracy and
precision than the estimated residual glomerular filtration
rate (GFR) obtained with the modification of diet in renal
disease (MDRD) formula. In this study, cystatin C levels
were taken from 215 hemodialysis and 95 chronic
ambulatory peritoneal dialysis patients to derive the
formula for RRF. The formula was then tested in a
validation group of 107 hemodialysis and 48 peritoneal
dialysis patients. The Hoek study [10] did not address the
contribution of dialytic clearance whether by hemodialysis
(HD) or PD to the plasma cystatin C levels. Dialytic
clearance must have an effect on cystatin C concentrations:
cystatin C is a cysteine protease inhibitor and a lowmolecular-weight protein (13.2 kDa) produced at a constant
rate by all nucleated cells [11]. Cystatin C would be
affected by dialytic clearance just like the low-molecularweight protein beta-2 microglobulin, albeit less in PD patients
than in high-flux hemodialysis patients [12]. Beta-2 microglobulin is commonly monitored in dialysis patients because
of its known associated morbidity, especially with regards to
amyloidosis [13].
In a recent study, Al Malki et al. [14] included
functionally anephric patients on conventional (3–5 h, three
times/week) hemodialysis, nocturnal hemodialysis (3–7
nights, 6–8 h), daily hemodialysis (6 days, 1.5–2.5 h) and
automated peritoneal dialysis and studied cystatin C levels.
The serum cystatin C levels were compared with urea
kinetic studies that included single pool Kt/Vurea and
standard weekly Kt/Vurea. It was found that the cystatin C
levels were indeed influenced by the method and intensity
of dialysis, and did show a significant negative correlation
with the standard weekly Kt/Vurea. The regression equation
indicated that for every increase in cystatin C of 1 mg/l, the
standard weekly Kt/V had decreased by 0.703. Because of
this, patients who were treated by nocturnal or daily
hemodialysis had statistically significantly lower mean
cystatin C levels than the conventional hemodialysis and
automated peritoneal dialysis groups. It was of interest that
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the cystatin C level was not correlated with the single
treatment, single pool Kt/Vurea. This study suggests that
cystatin C is dialyzable and that its serum or plasma
concentration will be dependent upon the balance between
its weekly generation and dialytic clearance together with
its volume of distribution. It is possible that the volume of
distribution, being a small molecular weight protein, is
confined to the extracellular space. Further studies are
therefore needed in anephric patients to examine the
changes in serum or plasma cystatin C levels over the
course of a number of individual hemodialysis or peritoneal
dialysis treatments and of the time-course of serum or
plasma cystatin concentrations following a change in
dialysis modality intensity. Comparisons of changes in serum
or plasma cystatin C levels to a small molecular weight
surrogates such as urea should answer these questions.
Cystatin C levels appear fairly stable in the dialysis
population and perhaps depend upon the certain consistency
of dialysis dose over time rather than be influenced by a single
treatment [14]. The fact that cystatin C concentration is not
influenced by the single pool Kt/V supports this concept. It
may be that the cystatin C level and single pool Kt/Vurea in a
dialysis patient is somewhat analogous to the hemoglobin
A1C level in its relationship to plasma glucose value in the
diabetic. In other words, the marker may reflect cumulative
middle molecule clearance over time. The stability may
be useful in that a given cystatin C level may allow the
rough estimation of both dialytic and residual renal
functional clearance, providing the total standard weekly
Kt/Vurea is known.
Studies in children remain scarce. With this context, we
read the Korean study on pediatric PD patients [7] with
great interest. In this study, nine patients who were anuric
did not demonstrate any correlation between the peritoneal
Kt/Vurea or the peritoneal weekly creatinine clearance. The
total Kt/Vurea was within a very narrow range in this group
(1.8–2.5). By contrast, the total weekly creatinine clearance
was 49.8 (range 36.2–66.3) L/week/1.73 m2, suggesting a
much wider range of dialysis prescriptions than indicated
by the total Kt/Vurea. For all patients, 24-h urine and
dialysate collections were performed at home, but in the
anuric group no collections were performed. Data on the
proportion of the nine patients who had both native kidneys
removed were not provided. By contrast, in the patients
with RRF, there was a significant negative correlation
between the cystatin C concentrations and the renal Kt/Vurea
(r=–0.793, p<0.001). The authors concluded that serum
cystatin C could be an appropriate marker for RRF,
independent of total and peritoneal Kt/Vurea.
Based on their observations, this conclusion is reasonable.
However, it is more likely that cystatin C levels are somewhat
affected by dialysis dose, as the determinants of cystatin C
concentrations during dialysis remain to be fully established.
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It is known that the intra-patient variability of cystatin C levels
is less than that of creatinine in children with CKD [15]. In a
recent study on 15 functionally anephric patients who
underwent cystatin C profiling during high-flux hemodialysis,
we established that cystatin C reduction ratio depended on
normalized blood liters processed and fluid removal during
hemodialysis. Those two parameters explained 81% of the
cystatin C variance. As outlined above, cystatin C values will
be affected by volume status because of the smaller volume of
distribution of cystatin C. In contrast to creatinine, cystatin C
is distributed only extracellular. The study by Kim et al. [7]
did not consider ultrafiltration in their model. Further studies
into serum cystatin C levels across dialysis and its
appearance in dialysate are indicated, as are further studies
in dialysis patients who have residual renal function [16].
The potential exists that serum cystatin C measurements may
be valuable for the monitoring of residual renal function and
delivered dialysis intensity plus the overall adequacy of
uremia management provided. This is particularly important
in view of the emerging importance of cystatin C as a marker
for pre-timely mortality [17].

References
1. Lowrie EG, Laird NM, Parker TF, Sargent JA (1981) Effect of the
hemodialysis prescription of patient morbidity: report from the
national cooperative dialysis study. N Engl J Med 305:1176–1181
2. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T,
Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT,
Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman
G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study
Group (2002) Effect of dialysis dose and membrane flux in
maintenance hemodialysis. N Engl J Med 347:2010–2019
3. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A,
Moran J, Mujais S, Mexican Nephrology Collaborative Study
Group (2002) Effects of increased peritoneal clearances on
mortality rates in peritoneal dialysis: ADEMEX, a prospective,
randomized, controlled trial. J Am Soc Nephrol 13:1307–1320
4. Bargman JM, Thorpe KE, Churchill DN (2001) Relative
contribution of residual renal function and peritoneal clearance
to adequacy of dialysis: a reanalysis of the CANUSA Study. J Am
Soc Nephrol 12:2158–2162

335
5. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC,
Boeschoten EW, Krediet RT (2004) Relative contribution of
residual renal function and different measures of adequacy to
survival in hemodialysis patients: an analysis of the Netherlands
Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J
Am Soc Nephrol 15:1061–1070
6. National Kidney Foundation (2006) 2006 updates clinical practice
guidelines and recommendations. Hemodialysis adequacy, peritoneal
dialysis adequacy and vascular access. Am J Kidney Dis 48(suppl 1):
S1–S322
7. Kim SJ, Sohn YB, Park SW, Jin DK, Paik KH (2010) Serum
cystatin C for estimation of residual renal function in children on
peritoneal dialysis. Pediatr Nephrol. doi:10.1007/s00467-0101678-8
8. Delaney MP, Stevens PE, Al Hasani M, Stowe HJ, Judge C, Lamb
EJ (2008) Relationship of serum cystatin C to peritoneal and renal
clearance measures in peritoneal dialysis: a cross-sectional study.
Am J Kidney Dis 51:278–284
9. Ros S, Bajo A, del Peso G, Garcia de Miguel A, Santacruz S,
Fernandez E, de Garcia R, Selgas R (2007) Cystatin C as marker
of residual renal function in patients on peritoneal dialysis:
relations with parameters of peritoneal function. J Nephrol
20:468–473
10. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT
(2007) Estimation of residual renal glomerular filtration rate in
dialysis patients from the plasma cystatin C level. Nephrol Dial
Transplant 22:1633–1638
11. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú
C, Grubb A (2005) Cystatin C as a marker of GFR–history,
indications, and future research. Clin Biochem 38:1–8
12. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y (2006)
Superior dialytic clearance of beta(2)-microglobulin and p-cresol
by high-flux hemodialysis as compared to peritoneal dialysis.
Kidney Int 70:794–799
13. Jadoul M, Garbar C, Vanholder R, Sennesael J, Michel C, Robert
A, Noël H, van Ypersele de Strihou C (1998) Prevalence of
histological beta2-microglobulin amyloidosis in CAPD patients
compared with hemodialysis patients. Kidney Int 54:956–959
14. Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM
(2009) Cystatin C levels in functionally anephric patients
undergoing dialysis: the effect of different methods and intensities.
Clin J Am Soc Nephrol 4:1606–1610
15. Sambasivan AS, Lepage N, Filler G (2005) Cystatin C intrapatient
variability in children with chronic kidney disease is less than
serum creatinine. Clin Chem 51:2215–2216
16. Lindsay RM, Huang SH, Filler G (2010) Cystatin C measurements in
the assessment of residual renal function, dialysis adequacy, and
beyond. Perit Dial Int 30:437–439
17. Hansson LO (2010) Cystatin C: an emerging marker for pre-timely
mortality. J Intern Med 268:106–108

